October 17, 2022 – Cambridge Isotope Laboratories, Inc. Embarks on Largest Expansion Project in the Company's History
TEWKSBURY, Mass., October 17, 2022 - Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), has embarked on the largest expansion in the company's history. This strategic undertaking, which has been aptly named North Star, will significantly increase 13C production by building a separate cryogenic distillation facility for carbon monoxide.
September 26, 2022 – Cambridge Isotope Laboratories, Inc. (CIL) Partners With ISOtopic Solutions to Release the New Stable Isotope-Labeled and Unlabeled Crude Lipid Yeast Extracts
Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts. These are designed to render 100s of fatty acids and lipids for use in MS lipidomics research and development.
August 11, 2022 – CIL Announces New Hire John Bakke as Vice President of Finance
Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of John Bakke as Vice President of Finance. John reports directly to the CEO, Cliff Caldwell.
March 31, 2022 – Otsuka Subsidiary to Receive Payment and Royalties from US Approval of Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer
Otsuka Pharmaceutical Co., Ltd (Otsuka) is pleased to announce that ABX advanced biochemical compounds GmbH (ABX), a subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), which in turn is a wholly owned subsidiary of Otsuka, expects to receive payments and royalties from Endocyte Inc., a Novartis company, based on the US FDA regulatory approval of Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan), formerly referred to as 177Lu-PSMA-617, a radioligand therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
February 7, 2022 – Cambridge Isotope Laboratories, Inc. (CIL) Hires Ashley Schultz as New Regional Sales Manager
Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the hire of Ashley Schultz as a new Regional Sales Manager. Schultz will lead sales for CIL in the Mid-Atlantic and Southeast regions, covering Pennsylvania, Delaware, Maryland, West Virginia, Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Alabama, Georgia, and Florida.
October 6, 2021 – Cambridge Isotope Laboratories, Inc. (CIL) Launches Stable Isotope-Labeled and Unlabeled TCA Cycle Multi-component Mixes
Tewksbury, MA - Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of our new stable isotope-labeled and unlabeled TCA cycle mixes to aid in the analysis of TCA-associated compounds in metabolic studies. The TCA (tricarboxylic acid) cycle, also known as the Krebs or citric acid cycle, plays an essential role in central carbon and energy metabolism. The study of its intermediates, and its ancillary compounds, has proven pivotal in not only understanding their impact on metabolism but also in profiling their function in oncogenesis, inflammation, and other pathologies.
September 10, 2021 – Otsuka Group of Companies Celebrates 100th Anniversary with New Symbol and Tagline
Otsuka Group Companies (parent company of Cambridge Isotope Laboratories, Inc.) began to celebrate its 100th anniversary on Sept. 1, 2021. Under the umbrella of Otsuka Holdings Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi), the Otsuka group consists of 194 companies, including Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., and Taiho Pharmaceutical Co., Ltd. Representing the entire group, Cambridge Isotope Laboratories would like to convey its appreciation for the patronage and support that has facilitated this milestone.
August 31, 2021 – Cambridge Isotope Laboratories, Inc. Is Now Offering Cannabis Standards for MS-based Testing
CIL now offers solutions for testing the quality and safety of cannabis products with the launch of a variety of stable isotope-labeled and native standards of THC, CBD, and other cannabinoids to assist with testing needs.
July 7, 2021 – Cambridge Isotope Laboratories, Inc. Announces the First Commercially Available Quantum-Grade Gas, 12C Methane QG-alpha™, for High-Performance Nitrogen-Vacancy (NV) Center Diamonds
Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, is proud to launch the first commercially available 12C-enriched methane-grade gas for quantum applications.
March 29, 2021 – Cambridge Isotope Laboratories, Inc. and Bruker Biospin Announce Strategic Partnership for the Global Distribution of CIL’s NMR Solvents
Cambridge Isotope Laboratories, Inc. is entering a global, strategic partnership with Bruker BioSpin for the distribution of CIL’s NMR solvents.
December 16, 2020 – Cambridge Isotope Laboratories, Inc. Announces 13C Cascade Production Optimization at Ohio Plant
Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently began a significant capacity optimization of one of the production cascades at the 13C separation facility in Xenia, Ohio. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade’s 13C production by 10%. This follows the most recent expansion completion earlier this year, which increased 13C production capacity by 25%.
September 22, 2020 – Eurisotop Responds to Market Demand for Deuterated Chloroform
Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NMR solvents and is the premier supplier of CIL stable isotope-labeled compounds in Europe. Eurisotop initially operated one reactor that produced 6 tons of deuterated chloroform per year. This new expansion consisted of adding a second reactor (twin reactors) and when operating simultaneously and continuously can produce tens of tons of product per year.
September 2, 2020 – Cambridge Isotope Laboratories, Inc. Expands Benzene and Bromobenzene Capacities to Meet Customer Demands
Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotopes and stable isotope-labeled compounds, recently announced a capacity expansion for deuterated benzene at Cambridge Isotope Separations, LLC (CIS), located on 33 acres in Xenia, Ohio. This capacity expansion started in the summer of 2019 and consisted of two new reactors being added; the first was active in January 2020 and the second new reactor came online this summer. To complete the final phase of this expansion, an additional distillation unit will be active by the end of 2020. This is the first deuterated benzene capacity expansion at CIS since the process began in 2008.
August 12, 2020 – Cambridge Isotope Laboratories, Inc. Announces Expansion of 13C Capacity at Ohio Plant
Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently completed a significant expansion of its 13C separation facility. In 1987, CIL took the initiative to construct the world’s largest 13C isotope-separation plant, Cambridge Isotope Separations, LLC (CIS), located on 33 acres in Xenia, Ohio.13C is a critical starting material supporting development of new research and diagnostic chemicals. Following expansions in 1996, 2012, and 2015, CIL embarked on a new expansion in 2018 which was completed earlier this year. This most recent expansion increased production capacity of 13C by 25%.
July 29, 2020 – Cambridge Isotope Laboratories Appoints Todd Osiek, PhD as Chief Science Officer
Cambridge Isotope Laboratories, Inc., the leading manufacturer of stable isotope and stable isotope-labeled compounds worldwide, is pleased to announce the addition of Todd Osiek, PhD, as Chief Science Officer (CSO). Osiek reports directly to the CEO, Cliff Caldwell. As CSO, Osiek is responsible for supporting operations development of best practices in safety and quality, working with sales and marketing on new-product development, and mapping out strategic directions and opportunities.
July 15, 2020 – Cambridge Isotope Laboratories Appoints Warren Arenz as Vice President of Operations
Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of Warren Arenz as Vice President of Operations. Arenz reports directly to the CEO, Cliff Caldwell.
July 2, 2020 – In the Wake of COVID-19, CIL Holds Local Food Drive
CIL recognizes the high level of food insecurities due to COVID-19 and wanted to give to the surrounding communities in need.To help those facing food insecurity in the wake of the COVID-19 outbreak, CIL held a food and personal care item drive supporting the Lawrence YMCA Food Pantry, partner of the Merrimack Valley Food Bank, Inc.
June 10, 2020 – Cambridge Isotope Laboratories Signs Distribution Agreement with FB Reagents to Sell Deuterated Phospholipids and Detergents
Cambridge Isotope Labs (CIL) is proud to offer an assortment of deuterated phospholipids and detergents manufactured by FB Reagents, Ltd. These compounds are being used to solubilize isotopically labeled membrane proteins for high-field nuclear magnetic resonance (NMR) spectroscopy, and to study membrane structure by small-angle neutron scattering (SANS). FBR’s products expand significantly CIL’s current offering of deuterated lipids and detergents.
June 4, 2020 – CIL Aids COVID-19-Related Research at MIT with 13C6 Glucose
CIL is aiding COVID-19-related research currently being conducted in the laboratory of Dr. Mei Hong, a professor of chemistry at MIT (Cambridge, MA.). The Hong laboratory develops and applies magic-angle-spinning solid-state NMR spectroscopy to elucidate the structure and dynamics of biological macromolecules. One current research focus of the Hong group is to determine the structure and binding mechanism of a severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) membrane protein.
May 18, 2020 – Cambridge Isotope Laboratories Partners with Alsachim in the Fight Against COVID-19
Through a commercial partnership with Alsachim, Cambridge Isotope Labs (CIL) is proud to now offer an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.
March 17, 2020 – CIL's Response to Coronavirus (COVID-19)
As we continue to monitor and respond to the changing business dynamics created by the Coronavirus (COVID-19), the entire CIL team extends our best wishes to you, your employees and families for good health and peace of mind during a difficult time.
October 29, 2019 – Cliff Caldwell Appointed CEO of CIL
CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL Canada in Montreal, Canada; CIL China in Shanghai; ABX in Dresden, Germany; and Eurisotop in Saclay, France.
January 23, 2018 – Otsuka Signs Statement of Support for Women’s Empowerment Principles
Cambridge Isotope Laboratories, Inc. (CIL), an indirect subsidiary of Otsuka Holdings Co., Ltd., announces that the latter has signed the CEO Statement of Support for the Women’s Empowerment Principles (WEPs), a set of Principles focusing on corporate action to promote gender equality and women’s empowerment in the workplace, marketplace and community.
October 2, 2017 – Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
West Lafayette, Ind., Oct. 2, 2017 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyte intends to move quickly into Phase 3 development of 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC).
April 26, 2017 – In the News – Food and Drug Administration (FDA) Approves the First Deuterated Drug, AUSTEDO™ by Teva
Cambridge Isotope Laboratories, Inc. is pleased that the Food and Drug Administration (FDA) approved the first deuterated drug, AUSTEDO™ by Teva (previously referred to as SD-809).
May 6, 2016 – CIL Successfully Holds Symposia on Chinese POPs Research Using Isotope Dilution Mass Spectrometry
POPs research is growing rapidly in China, and use of Isotope Dilution MS has been shown to be the most robust method for accurate and precise POPs analysis. Cambridge Isotope Laboratories, Inc. (CIL) is partnered with RCEES,Tongji University and Zhejiang University to hold three symposia for Chinese POPs research using Isotope Dilution Mass Spectrometry. CIL is the global leader in separation of stable isotopes and manufacture of stable isotope-labeled compounds, and wishes to help expand the communication and collaboration of current POPs research in China.
January 31, 2014 – Cambridge Isotope Laboratories and Nexomics Biosciences Sign an Exclusive Worldwide Commercial Supply Agreement
Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched small molecules, is working together with Nexomics Biosciences, a structural biology and protein production contract research organization, to provide isotope-labeled proteins to life science research organizations.
August 8, 2008 – Cambridge Isotope Laboratories and CellFree Sciences (CFS) Announce Distribution Agreement
CIL, the world’s leader in the manufacturing of stable isotope-labeled research chemicals, has entered into a distributor agreement with CellFree Sciences Co., Ltd. for the distribution of CFS’s WEPRO Expression Kits and reagents for cell-free protein production for NMR and mass spectrometry applications in North America and Europe. CIL will provide stable isotope-enriched amino acids as a component in the WEPRO Expression Kits.
